Home>Topics>Stocks>Endo Pharmaceutical Holdings

Endo Pharmaceutical Holdings ENDP

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. Headlines
    1. Nektar 181 Could Dominate A $13B Chronic Pain Market

      Headlines

      Tue, 26 Aug 2014

      capsules into a quickly absorbed powder and switched to alternative pain killing narcotics like Opana. Endo Pharmaceutical s ( ENDP ), makers of Opana, then mad e their own tamper resistant formula that is now struggling to achieve pre-resistant sales

    2. Endo International's ( ENDP ) CEO Rajiv Kanishka Liyanaarchchie De Silva on Q2 2014 Results - Earnings Call Transcript

      Headlines

      Thu, 31 Jul 2014

      Endo International (NASDAQ: ENDP ) Q2 2014 Earnings Call July 31, 2014 8:30 am ET Executives Blaine T. Davis - Senior Vice President of Corporate Affairs and

    3. Endo updated guidance after Q2 results

      Headlines

      Thu, 31 Jul 2014

      Endo International ( ENDP +0.9% ) Q2 results : Revenues: $718.7M (+0.9%); Cost of Revenues: $345.7M (+26.4%); Operating Income

    4. Endo beats by $0.17, beats on revenue

      Headlines

      Thu, 31 Jul 2014

      Endo (NASDAQ: ENDP ): Q2 EPS of $1.06 beats by $0.17 . Revenue of $718.6M (+0.9% Y/Y) beats by $74M . Press Release Post your comment!

    5. Notable earnings before Thursday’s open

      Headlines

      Wed, 30 Jul 2014

      CCJ , CDW , CEVA , CHTR , CI , CL , CME , CNSL , COMM , COP , COT , CRCM , CRR , CTCM , CVI , CVRR , DDD , DISCA , DLPH , DTV , ENDP , EPD , EXC , FCH , FCN , FIG , FLY , FRM , GEL , GG , GIL , GLOP , GMT , GNRC , GTLS , H , HGG , HL , HP , HST , IDA , IMN

    6. Credit Market Outlook: Tight Spreads Will Keep a Lid on Returns

      Headlines

      Thu, 26 Jun 2014

      to pursue acquisitions that boost their currently lackluster growth prospects. While Teva TEVA "> TEVA and Endo 's ENDP "> ENDP notes appear to compensate investors for that event risk, Mylan 's MYL "> MYL notes do not, which keeps it on our

    7. Our Outlook for the Credit Markets

      Headlines

      Fri, 27 Dec 2013

      narrow moat) has steadily reduced its debt such that leverage has declined to 1.2 times from 2 times. Endo Health Solutions ENDP (rating: BB, narrow moat) has announced that it is using equity to fund an acquisition, which will help the firm diversify

    8. Endo's New CEO Shakes Up Firm With Restructuring Plan and Management Changes

      Commentary

      Thu, 6 Jun 2013

      After just three months on the job, Endo Health Solutions ENDP CEO Rajiv De Silva announced that he is spearheading a major restructuring effort at the specialty health-care company. This

    9. Strong Generic Performance Offsets Weak Branded Sales in Endo's In-Line 1Q

      Commentary

      Tue, 7 May 2013

      Endo Health Solutions ENDP reported first-quarter results that met our expectations for increased competition in its core branded pharmaceutical division

    10. Endo Ekes Out Earnings Growth in 2012; Generic Entrants to Cause Sales and Earnings Declines in 2013

      Commentary

      Fri, 1 Mar 2013

      Endo ENDP reported net revenue of USD 3.03 billion and USD 5.02 per share in earnings for the year, at the bottom end of its prior guidance

    « Prev12345Next »
    Content Partners